WO1997040818A1 - Biologically active composition - Google Patents

Biologically active composition Download PDF

Info

Publication number
WO1997040818A1
WO1997040818A1 PCT/SE1997/000721 SE9700721W WO9740818A1 WO 1997040818 A1 WO1997040818 A1 WO 1997040818A1 SE 9700721 W SE9700721 W SE 9700721W WO 9740818 A1 WO9740818 A1 WO 9740818A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
weight
biologically active
fatty acid
ceding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1997/000721
Other languages
English (en)
French (fr)
Inventor
Åke LINDAHL
Rickard Bryland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioglan AB
Original Assignee
Bioglan AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan AB filed Critical Bioglan AB
Priority to DE69736985T priority Critical patent/DE69736985T2/de
Priority to US09/155,642 priority patent/US6979454B1/en
Priority to AU27969/97A priority patent/AU701720B2/en
Priority to NZ332497A priority patent/NZ332497A/xx
Priority to EP97922252A priority patent/EP0952819B1/en
Priority to JP53881597A priority patent/JP4283892B2/ja
Priority to CA002251702A priority patent/CA2251702C/en
Publication of WO1997040818A1 publication Critical patent/WO1997040818A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to the field of biolo ⁇ gically active compositions and, in particular, to a bio- logically active stick composition.
  • the inven ⁇ tion relates to pharmaceutical compositions but, other applications outside the medical field are possible wit ⁇ hin the scope of the invention.
  • the invention also relates to the use of such compo- sitions as medicaments and for the manufacture of stick medicaments for treating dermal conditions, as well as to a process for the preparation of such compositions.
  • BACKGROUND OF THE INVENTION One of the problems associated with topical medical treatment with high potency drugs is in the application of the composition. Most compositions intended for derma- tological treatment of the skin are based on cream, oint ⁇ ment of gel vehicles and, when these are applied to the skin, the incidence of extralesional treatment can be substantial; areas surrounding the lesion to be treated as well as the fingers used to apply a product can be af ⁇ fected by the drug.
  • stick compositions having higher viscosi ⁇ ties which can be housed within a protective package, such extralesional treatment can be avoided or at least substantially eliminated.
  • Another advantage of stick for ⁇ mulations is that, by their use, it is simple to achieve a uniform distribution of drug over the lesion to be tre ⁇ ated.
  • Stick based products are not novel in the treatment of skin conditions and several active compounds have been formulated into sticks.
  • Stick compositions, as herein re ⁇ ferred to, are formed from erodible, usually soft and waxy materials having a solid consistency. When rubbed across the skin, such compositions are eroded and deposit a coating of their constituent material on the skin.
  • stick compositions include mixtures of lipids and surfactants as carriers.
  • a corticosteroid stick product containing propylene glycol or 1,3-butylene glycol is previously known from US 4,299,828.
  • said product is not based on the use of an unsaturated fatty acid alcohol as a solvent and the alkylene glycols referred to are not utilized as sol ⁇ vents but rather as anti-microbial compounds.
  • said anti-microbial compound is not dissolved in the stick but dispersed the ⁇ rein (col 3 lines 35-40 and claim 1), i.e. the stick is not a homogeneous product.
  • the pre ⁇ ferred percentage of the alkylene glycol is disclosed as 2-10 and optionally 3-8 % by weight (col 3 lines 20-22 and claim 1) .
  • the purpose of the alkylene glycol is completely different from that of the present invention where higher percentages of alkylene glycol have been found to give other effects than those referred to in US 4,299,828.
  • the present invention relates to a completely novel solid composition, especially a stick composition, for biologically active agents, which may seem similar to the aforementioned lipid based stick products, but which is of a completely different structure and thereby possessed of completely different properties as compared thereto.
  • the solid compositions according to the present invention do not rely upon mechanical me ⁇ ans to ensure uniform distribution of the biologically active agent.
  • the active agent is distributed in a lipid carrier, but not in a suspended or dispersed state as previously practised but, rather, in a dissolved state.
  • a first object of the invention is to provide a com ⁇ position which contains a biologically active agent in a dissolved state.
  • Another object of the invention is to provide a com ⁇ position which possesses an enhanced stability against sedimentation of the active agent.
  • Still another object of the invention is to provide homogeneous compositions.
  • One other object of the invention is to provide a composition for use as a drug or medicament, especially for the treatment of dermatological conditions.
  • Still another object of the invention is to provide a process for the preparation of compositions, especially stick compositions of the type referred to above. Still other objects of the invention should be ob ⁇ vious to a person skilled in the art after having studied the following description of the invention.
  • a solid composition comprising a biologically active agent dissolved in a carrier sys ⁇ tem, wherein the carrier system includes a specific com ⁇ bination of solvents for the active agent and a stiffe ⁇ ning agent for imparting a solid consistency to the com ⁇ position.
  • the stiffening agent is a viscosity enhancing agent capable of imparting a soft and erodible consistency to the composition.
  • compositions in accordance with the present invention are stick compositions as hereinbe ⁇ fore defined.
  • the carrier system includes an unsaturated fatty acid alcohol in combination with an alkylene glycol se ⁇ lected from propylene glycol, butylene glycol, dipropyle ⁇ ne glycol and/or dibutylene glycol as a solvent for the active agent and a stiffening agent for imparting a solid consistency to the composition, said alkylene glycol being present in an amount that gives mutual dissolution with said unsaturated fatty acid alcohol as well as dis ⁇ solution of said active agent.
  • compositions in accordance with the invention can form stable stick compositions without any substantial sedimentation of the biologically active agent.
  • the solvent combination used should be capable of dissolving the biologically active agent at a temperature where significant decomposition of said agent is avoided.
  • the biologically active agent is any bio ⁇ logically active compound, or mixture of compounds, which can be dissolved to a substantial extent m the carrier system of the present invention.
  • the biologically active agent is a lipophilic, i.e. lipid soluble, compound.
  • the invention is of special interest in connection with drugs or medical compounds but, of course, the inventive idea is applicab ⁇ le to any biologically active agent for which a stick formulation is appropriate.
  • biologically active agent should be interpreted in a broad, conventional sense to mean an element, compound or composition which, when present in an effective amount, will interact with living organisms, preferably to elicit a therapeutic ef ⁇ fect.
  • compositions according to the invention there are a large number of agents falling within the avove-mentioned definitions and which can be formula ⁇ ted in compositions according to the invention.
  • agents e.g. corticoste- roids, vitamins, sex hormones, biologically active li- pids, fatty acids, antibiotics or antimicrobials and local anestetics.
  • steroids e.g. corticoste- roids
  • the compounds can be used per se or in the form of salts or esters or other chemi ⁇ cally modified forms thereof.
  • Some examples within the above-mentioned groups include vitamins A, D2, D3, E, K and derivatives thereof, androgens, estrogens and derivatives thereof, amide type local anestetics and antimicrobials such as antivirals, antibacterials, antiprotozoals and antifungals. Further examples include fluocinonide, omega-3-fatty acid and azelaic acid, and salts and esters thereof, clobetasol, and salts and esters thereof, and betamethasone and salts and esters thereof, particularly betamethasone-17- valerate and betamethasonedipropionate. Generally the solvent used is capable of dissolving the specific active agent used to the desired extent.
  • the solvent comprises an unsaturated C 16 -C2o ⁇ fatty acid alchol, more preferably C ⁇ B -fatty acid alcohol, in mutual dissolution with the alkylene alcohol referred to.
  • unsaturated C 18 -fatty acid alco ⁇ hol it is preferably selected from oleyl alcohol, rici- nolyl alcohol, linolyl alcohol and/or linolenyl alcohol and more preferably is oleyl alcohol.
  • C ⁇ 8 -fatty acid alcohol is eleosteryl alcohol
  • a preferable example of a C ⁇ 6 -fatty acid alcohol is palmi- toleyl alcohol
  • a preferable example of a C 2 o _ fatty acid alcohol is arachidonyl alcohol.
  • the unsaturated fatty acid al ⁇ cohol is used in combination with an alkylene glycol ha ⁇ ving the general formula R(OH) 2 ; a di- or poly-alkylene glycol having the general formula HOR (OR) n OROH; a C 4 -C 36 (e.g. C 4 -C ⁇ ) aliphatic primary alcohol; or a mixture of two or more such compounds.
  • each group R can be the same or different and is an al ⁇ kyl, preferably a C 2 -C 6 alkyl group and n ⁇ 0.
  • Preferred groups R are ethyl, propyl and butyl groups and the pre- ferred glycols thus include propylene glycol, butylene glycol, dipropylene glycol and dibutylene glycol.
  • unsaturated fatty acid alcohols other primary alcohols can be included in the composition, such as lauryl alcohol, myristyl alco- hoi, palmityl alcohol and/or stearyl alcohol.
  • an ad ⁇ ditional solvent can be included wich is selected from lipid esters, such as fatty acid esters and esters of sorbic acid.
  • fatty acids from which such es- ters can be derived include lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, ricinoleic acid, linolic acid and linolenic acid.
  • the precursor alcohols are preferably the Ci-Ce-alkanols methanol, etanol, pro ⁇ panol, butanol, pentanol and hexanol with either straight or branched carbon chains.
  • Especially preferred esters in this respect are the propyl esters, including the isopro ⁇ pyl esters, especially isopropylpalmitate.
  • Still further additional solvents usable in the in ⁇ vention are the C 2 -C6 alkylene carbonates, e.g. ethylene, propylene or butylene carbonate, preferably propylene carbonate.
  • the viscosity enhancing agent should be chosen such that it is compatible with the solvent and so that it im ⁇ parts the desired viscosity or consistency thereto.
  • said viscosity enhancing agent is a waxy substance.
  • said waxy substance is a natural or synthetic wax which is gener ⁇ ally defined as monoester of a long-chained (typically Ci4-C 36 , e.g. Ci 8 -C 2 4) carboxylic acid with a long-chained (typically Ci6-C 36 ) alcohol.
  • the carbon chains preferably, are unbranched aliphatic chains.
  • the waxy substance is a fat and, preferably, a triglyceride of a C ⁇ 8 -C 36 fatty acid or a glycol (typically an alkylene glycol as herein before defined and comprising 2-6 carbon atoms) ester of a C ⁇ 8 - C 36 fatty acid.
  • the viscosity enhancing agent com- prises a combination of a natural and/or synthetic wax plus a triglyceride and/or a glycol ester, as defined above, and enables the carrier system's rheological prop ⁇ erties to be accurately tailored, for example, to achieve a broad softening point.
  • Other preferred waxes are paraffin wax and cerasine wax.
  • the viscosity enhancing agent can cause the composition to be too vis ⁇ cous.
  • this can be avoided by incorporating into the carrier system an oil having the capacity to plasticize the viscosity en ⁇ hancing agent and reduce the viscosity of the carrier system to a level that is suitable for the composition ' s intended purpose.
  • Preferred plasticizing oils include low molecular weight aliphatic acids and alcohols, especially with branched chains, e.g. fluid lanoline.
  • the inventive composition is for use as a me ⁇ dicament, it should hardly need mentioning that all of the above-identified ingredients, as well as other op- tional conventional further ingredients, should be phar ⁇ maceutically acceptable and non-toxic when the composi ⁇ tion is used in the intended manner.
  • the combination of solvent and viscosity enhancing agent in the carrier system should be selected in line with the principles given above such that a proper disso ⁇ lution rate, consistency and release rate are obtained. Generally this means that the amounts of the different ingredients could be decided experimentally using tech ⁇ niques well known to persons skilled in the art.
  • the amount of solvent can be withm the range of 20-85 % by weight
  • the amount of viscosity enhancing agent can be within the range of 15-80 % by weight
  • the amount of plasticizing oil can be within the range of 0- 30 % by weight, based on the total weight of the car ⁇ rier system.
  • the amount of solvent is within the range of 25-75, more preferably 40-60, percent by weight, while the amount of viscosity enhancing agent is within the range of 15-55, more preferably 25-50, percent by weight and the amount of plasticizing oil is within the range of 0-30, more preferably 2-20, percent by weight.
  • the amount of alkylene glycol is more than 12 % by weight and preferably at least 15 % by weight, based on the total weight of the carrier system.
  • the amount of the alkylene glycol solvent, preferably propylene glycol is within the range of
  • the weight ra ⁇ tio of oleyl alcohol : additional solvent is within the range of 1:2 to 5:1, preferably 1:2 to 3:1 and more pref ⁇ erably 1:2 to 2:1.
  • the amount of the biologically active agent is of course dependent on the effect to be accomplished. Gener- ally, however, the upper limit will be the active agent s solubility limit in the carrier system, which can be up to 40 percent by weight or in some cases merely up to 10 or even 5 percent by weight, in all cases calculated on the weight of the carrier system. Preferably the range thereof can be 0.01 - 10, especially 0.02 - 5, percent by weight, on the same basis. The exact amount, however, is easily determined by a person skilled in the art with reference to the optimum or maximum effect it is wished to obtain. It is especially preferred that compositions accord ⁇ ing to the invention are for pharmaceutical or medical purposes. In this case, the biologically active agent can be a therapeutic or prophylactic agent of any kind. The other ingredients employed must be selected in accordance with the general principles applying to the formulation of medical or pharmaceutical compositions.
  • the inventive composition comprises a medicament for administration to the skin, or for dermal administration.
  • a person skilled in the art will formulate the composition such that its viscosity will be proper for administration in that way and such that the release of the active com ⁇ pound will have the desired profile.
  • stick compositions according to the present inven ⁇ tion are especially well suited for the treatment of der- matological conditions.
  • compositions preferably stick compositions, m accor ⁇ dance with the invention.
  • Said process comprises dissolv ⁇ ing the biologically active agent in the solvent there- for, combining the resulting solution with a viscosity enhancing agent so as to impart a solid consistency to said solution and shaping the resulting formulation into a stick.
  • the active agent is dissolved in the sol ⁇ vent, or part thereof, and the solution obtained is then added to a melted mass of the viscosity enhancing agent, preferably while being stirred.
  • said mass preferably after some cool- ing, can then be poured into a mould and allowed to cool and set in the desired shape. Proper temperatures in this respect are easily determined by a person skilled in the art.
  • the composition is physically stable below +50°C al- though softening of the structure may occur.
  • the composi ⁇ tion should be capable of returning to its original vis ⁇ cosity after cooling to +30°C or lower. This may also be valid after heating to temperatures in excess of +50°C. After such heating followed by cooling to +30°C or lower the composition will still be homogeneous. This is an advantage compared to such stick formulations where the active drug is in solid form, i.e. suspended. In these compositions the active drug will settle out at higher temperatures and form an unhomogeneous prepara- tion.
  • Stick compositions 1-10 were prepared from the fol ⁇ lowing ingredients, the figures being percentages by weight .
  • the manufacturing process was as follows:
  • the active agent was dissolved in the oleyl alcohol. Separately the lanoline, paraffin wax, ceresine wax, gly ⁇ col esters, triglycerides and the isopropyl pa-Imitate were mixed together in a glass beaker. The mixture in the glass beaker was then heated to about 75°C and was allowed to melt while being stirred. The oleyl alcohol and active agent solution, also heated to +75°C, was then added thereto and the combination was stirred for 10 minutes. After reducing the temperature to about 65°C the re ⁇ sulting composition was poured into a stick mould and al ⁇ lowed to cool and solidify.
  • compositions were then tested by means of con ⁇ ventional blanching tests (blanching is an established method of assaying biological activities of steroid preparations) and compared with commercial creams and ointments.
  • blanching is an established method of assaying biological activities of steroid preparations
  • results of said tests are summarized as follows :
  • composition No. 10 according to the invention was bioequivalent to all commercial cream and ointment products, which is in ⁇ deed unexpected and means a great contribution to the art now that a stick product can compete with well-estab- lished creams and ointments. Furthermore, it should be borne in mind that the new stick claimed possesses great advantages also compared to known stick products as has been described above (completely homogeneous product with no sedimentation problems, etc.).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/SE1997/000721 1996-04-30 1997-04-29 Biologically active composition Ceased WO1997040818A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69736985T DE69736985T2 (de) 1996-04-30 1997-04-29 Biologisch aktive zusammensetzung
US09/155,642 US6979454B1 (en) 1996-04-30 1997-04-29 Biologically active composition
AU27969/97A AU701720B2 (en) 1996-04-30 1997-04-29 Biologically active composition
NZ332497A NZ332497A (en) 1996-04-30 1997-04-29 Pharmaceutical composition having a carrier system containing a combination of an alkylene glycol and unsaturated fatty acid alcohol as the solvent and a stiffening agent
EP97922252A EP0952819B1 (en) 1996-04-30 1997-04-29 Biologically active composition
JP53881597A JP4283892B2 (ja) 1996-04-30 1997-04-29 生物学的活性を有する組成物
CA002251702A CA2251702C (en) 1996-04-30 1997-04-29 Biologically active composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9601665A SE9601665D0 (sv) 1996-04-30 1996-04-30 Biologically active composition
SE9601665-4 1996-04-30

Publications (1)

Publication Number Publication Date
WO1997040818A1 true WO1997040818A1 (en) 1997-11-06

Family

ID=20402417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1997/000721 Ceased WO1997040818A1 (en) 1996-04-30 1997-04-29 Biologically active composition

Country Status (12)

Country Link
US (1) US6979454B1 (cg-RX-API-DMAC10.html)
EP (1) EP0952819B1 (cg-RX-API-DMAC10.html)
JP (1) JP4283892B2 (cg-RX-API-DMAC10.html)
AT (1) ATE345777T1 (cg-RX-API-DMAC10.html)
AU (1) AU701720B2 (cg-RX-API-DMAC10.html)
CA (1) CA2251702C (cg-RX-API-DMAC10.html)
DE (1) DE69736985T2 (cg-RX-API-DMAC10.html)
ES (1) ES2276425T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ332497A (cg-RX-API-DMAC10.html)
SE (1) SE9601665D0 (cg-RX-API-DMAC10.html)
WO (1) WO1997040818A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA973705B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050889A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DK1871353T3 (da) * 2005-04-15 2011-04-04 Einstein Coll Med Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
US9428582B2 (en) * 2006-07-03 2016-08-30 Genmab A/S Method of treating rash in patients undergoing anti-EGFR therapy
ES2550481T3 (es) * 2007-08-16 2015-11-10 The University Of Chicago Resistencia a patógenos de plantas
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299828A (en) * 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
US4711906A (en) * 1984-12-21 1987-12-08 Merckle Gmbh Liquid diclofenac preparations
US5174995A (en) * 1986-12-11 1992-12-29 Beecham Group P.L.C. Topical drug release system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299828A (en) * 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
US4711906A (en) * 1984-12-21 1987-12-08 Merckle Gmbh Liquid diclofenac preparations
US5174995A (en) * 1986-12-11 1992-12-29 Beecham Group P.L.C. Topical drug release system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050889A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents

Also Published As

Publication number Publication date
NZ332497A (en) 1999-05-28
SE9601665D0 (sv) 1996-04-30
ATE345777T1 (de) 2006-12-15
CA2251702A1 (en) 1997-11-06
AU701720B2 (en) 1999-02-04
AU2796997A (en) 1997-11-19
ES2276425T3 (es) 2007-06-16
JP2000509385A (ja) 2000-07-25
DE69736985T2 (de) 2007-09-20
CA2251702C (en) 2007-01-09
ZA973705B (en) 1997-11-25
JP4283892B2 (ja) 2009-06-24
US6979454B1 (en) 2005-12-27
EP0952819B1 (en) 2006-11-22
EP0952819A1 (en) 1999-11-03
DE69736985D1 (de) 2007-01-04

Similar Documents

Publication Publication Date Title
US5104656A (en) Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
WO1993000106A1 (en) External preparation containing cyclosporin
US5026556A (en) Compositions for the transdermal delivery of pharmaceutical actives
AT400517B (de) Topisches terbinafinpräparat und verfahren zu seiner herstellung
AU9002601A (en) Novel topical oestroprogestational compositions with systemic effect
WO1991007169A1 (en) Glyceryl acetate ointment vehicles
JPS63150221A (ja) 結晶性薬物含有乳化組成物
FI69753B (fi) Foerfarande foer framstaellning av en salva pao basis av isosorbiddinitrat
EP0471084B1 (en) Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic
EP0952819A1 (en) Biologically active composition
JP2860748B2 (ja) 安定な酪酸ヒドロコルチゾン含有クリーム剤
JP2015227354A (ja) モメタゾンとプロピレングリコールとの水中油型エマルジョン
WO1994026234A1 (en) Water-in-oil emulsion compositions
JPH07304669A (ja) 痔疾治療用組成物
JP3803595B2 (ja) 尿素含有皮膚外用組成物
JPH06271420A (ja) 化粧料または皮膚外用剤の吸水性改善剤
JPH0764734B2 (ja) 経皮投与製剤
EP3362045B1 (en) A process for preparing a composition comprising a high concentration of one or more avermectins
SK70497A3 (en) External antiinflammatory agent and method of producing it
AU669829B2 (en) Stable dermatologic preparation containing mycophenolic acid
RU2148998C1 (ru) Фармацевтическая или ветеринарная композиция (варианты) и способ получения композиции
JPH06287137A (ja) スルホニウム化合物含有皮膚外用剤
JPH07116046B2 (ja) 経皮投与製剤
SK141993A3 (en) Treatmental unguent without irritative reaction for skin and the method of its preparation
EP2429490A1 (en) Oil-in-water emulsion of mometasone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997922252

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09155642

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2251702

Country of ref document: CA

Ref country code: CA

Ref document number: 2251702

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 332497

Country of ref document: NZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997922252

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997922252

Country of ref document: EP